がん研セミナー（12月12日）のお知らせ

演題：Breast cancer: From Big Genomic Data to Precision Medicine

演者：Dr. Siew-Kee (Amanda) Low

Faculty of Pharmacy, The University of Sydney, NSW

Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, RIKEN, Japan.

抄録：The common disease-common variant hypothesis postulated the cumulative effects of common genetic variations, represented by single nucleotide polymorphism (SNP), are associated with the susceptibility of complex diseases, responsiveness to drugs and likelihood of adverse drug reactions.  Genome-wide association study (GWAS) is an approach to evaluate the associations of SNPs with various phenotypes across the genome.  The identification of common genetics variations could facilitate the establishment of prediction model in pharmacogenomics study and disease susceptibility, also, it helps to improve the understanding of complex diseases pathogenesis.  With the emergence of next generation sequencing (NGS) that aim to evaluate all genetic variations that include rare, intermediate and common variations in the genome have subsequently contribute to the rapid establishment of big genomic data.  The advancement of NGS has revolutionized the utilization of genetic information in clinical settings that aids to accomplish the promise of precision medicine.  Currently, tumour mutation profiling could facilitate tumour assessment, tumour classification, identification of actionable mutation that could be used as the target by various targeted therapy to optimize treatment efficacy and minimize toxicity.  In this seminar, I will illustrate the utilization of GWAS and NGS to identify genetic markers that are associated with the susceptibility of breast cancer and pharmacogenomics studies of drug-induced toxicity in breast cancer patients from the Japanese population.  In addition, I will also discuss the potential of NGS in cancer precision medicine.  My main research interest is to integrate genetic information into clinical setting by utilizing various genetic screenings and NGS to facilitate cancer detection, sequence-guided therapy, drug repurposing, pharmacogenomics studies and cell-free DNA monitoring to evaluate tumour recurrence as well as drug resistance for cancer patients.

日時：２０１６年１２月１２日（月）１６：００〜１７：００

場所：吉田講堂

連絡先：野田哲生（内線５２３１）

＊外部の研究者のご来聴を歓迎いたします。尚、本セミナーの内容は専門的であり、医学・生物分野の研究に携わる方を対象としております。